评估药品监管干预措施的影响:系统综述与方法学考量
该系统综述检索MEDLINE和EMBASE截至2017年3月的文献,纳入153篇评估欧盟或非欧盟监管行动影响的英文文章进行描述性分析。研究发现研究设计和报告存在显著异质性,多数研究评估药物利用变化,很少评估非预期后果,亟需科学指南规范方法学。
要点
- 监管干预影响评估多采用前后时间序列设计(三分之二),分析方法以中断时间序列回归为主(31.4%)。
- 仅27%的研究评估健康结局,18%评估知识、行为或临床实践变化,非预期后果评估罕见。
- 研究设计和报告异质性大,亟需科学指南确保稳健方法的应用和结果的系统传播。
核心结论
- 药品监管干预影响评估研究增多,但研究实施和报告异质性显著,需要科学指南规范方法学并系统传播结果。
研究设计与样本
- 系统综述,检索MEDLINE和EMBASE截至2017年3月,最终纳入153篇英文文章进行描述性分析。
主要发现
- 超过三分之一文章研究镇痛药和抗抑郁药;55%研究测量药物利用模式变化,27%评估健康结局,18%针对知识、行为或临床实践变化。
- 非预期后果如转换治疗或溢出效应很少被评估;三分之二使用前后时间序列设计,15.7%使用前后横断面设计。
- 分析方法包括中断时间序列回归(31.4%)、简单描述性分析(28.8%)和带显著性检验的描述性分析(23.5%)。
关键数值与推荐
- 最常评估的干预类型为监管安全通讯(28.8%)、黑框警告(23.5%)和直接医疗专业人员通讯(10.5%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Evaluating the public health impact of regulatory interventions is important but there is currently no common methodological approach to guide this evaluation. This systematic review provides a descriptive overview of the analytical methods for impact research. METHODS: We searched MEDLINE and EMBASE for articles with an empirical analysis evaluating the impact of European Union or non-European Union regulatory actions to safeguard public health published until March 2017. References from systematic reviews and articles from other known sources were added. Regulatory interventions, data sources, outcomes of interest, methodology and key findings were extracted. RESULTS: From 1246 screened articles, 229 were eligible for full-text review and 153 articles in English language were included in the descriptive analysis. Over a third of articles studied analgesics and antidepressants. Interventions most frequently evaluated are regulatory safety communications (28.8%), black box warnings (23.5%) and direct healthcare professional communications (10.5%); 55% of studies measured changes in drug utilization patterns, 27% evaluated health outcomes, and 18% targeted knowledge, behaviour or changes in clinical practice. Unintended consequences like switching therapies or spill-over effects were rarely evaluated. Two-thirds used before-after time series and 15.7% before-after cross-sectional study designs. Various analytical approaches were applied including interrupted time series regression (31.4%), simple descriptive analysis (28.8%) and descriptive analysis with significance tests (23.5%). CONCLUSION: Whilst impact evaluation of pharmacovigilance and product-specific regulatory interventions is increasing, the marked heterogeneity in study conduct and reporting highlights the need for scientific guidance to ensure robust methodologies are applied and systematic dissemination of results occurs.
引用
- Goedecke T, Morales DR, Pacurariu A, et al. Measuring the impact of medicines regulatory interventions - Systematic review and methodological considerations. Br J Clin Pharmacol. 2017. PMID: 29105853. doi:10.1111/bcp.13469
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。